Deutsche Bank analyst George Hill lowered the firm’s price target on HealthEquity to $69 from $72 and keeps a Buy rating on the shares. The company ended a "strong" fiscal year with "another solid beat" in Q4, along with "the best year of new HSAs from sales and the highest level of HSA accounts and assets," the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HQY:
- HealthEquity sees FY24 EPS $1.74-$1.87, consensus $1.76
- HealthEquity reports Q4 EPS 0c, consensus 35c
- HealthEquity Reports Fiscal Year and Fourth Quarter Ended January 31, 2023 Financial Results
- HealthEquity Sets Date to Announce Fourth Quarter and Fiscal Year End Results
- HealthEquity Reports Record HSA Sales, Asset Growth